Soluble SARS Coronavirus Spike Protein (S Protein)
Description of Invention:
The SARS coronavirus is etiologically linked to severe acute respiratory syndrome. Soluble forms of the SARS coronavirus spike protein have been cloned, expressed and characterized, and are available for licensing for use as research reagents, in the development of vaccines and inhibitors of the viral infection, for selection of monoclonal antibodies, and development of kits containing antibodies that bind to the spike protein. The filed patent application additionally claims the associated spike protein polypeptides, peptide fragments, and conserved variants thereof; nucleic acid segments and constructs that encode the spike protein, polypeptides and peptide fragments of the spike protein, and conserved variants thereof and coupled proteins that include the spike protein or a portion thereof and peptidomimetics.
Inventors:
Dimiter Dimitrov and Xiadong Xiao (NCI)
DHHS Reference No. E-228-2003/2 --
PCT Application No. PCT/US04/23345 filed 20 Jul 2004, which published as WO 2005/010034 on 03 Feb 2005
U.S. Patent Application No. 11/335,197 filed 19 Jan 2006
Related Technologies: DHHS Reference No. E-334-2003 -- Enhanced Sensitivity ELISA for SARS Diagnostic
For Additional Information Please Contact: Michael Shmilovich J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5019
Email: shmilovm@mail.nih.gov
Fax: (301) 402-0220
